Fritextsökning
Innehållstyper
-
Higher throughput in less time
Do you want to automate your quality processes, shorten inspection times and increase your throughput? Gain inspiration from the experience of the medical techn...
-
Microscope and measuring machine in one
ZEISS O-INSPECT duo covers two essential applications in quality assurance.
-
NorthX Biologics Matfors AB
-
”Vill Sverige vara ett innovationsland? Addera konst till life science”
Sverige behöver nya grepp för att säkra framtidens kompetens inom life science. Genom att förena konst och skapande med vetenskap kan området bli mer begripligt...
-
Raised millions to develop a treatment for ´butterfly children´
Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 100 million in a new...
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
Don't miss out on this unique opportunity
ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.
-
Novo Nordisk to invest billions in Danish manufacturing facilities
Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...
-
Galderma
-
ZEISS Quality Innovation Days
The leading digital event from April 15-19, 2024.
-
A+ Science AB
-
“Life science is important on a personal level”
From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...
-
Aurevia
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
Bio-Works
-
Marie Gårdmark: ”The situation is not satisfactory”
”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients...
-
HAB Nicolai Johannsen
-
Catalent kapar bort 350 tjänster inom genterapi
CDMO-bolaget Catalent säger upp 350 av sina anställda inom genterapiproduktion i USA.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...
-
Anna Törner: Vem betalar för Rebecca Doe – och alla oss andra?
Det lätt att vänja sig vid tanken att vård och läkemedel är gratis, när det egentligen handlar om hur och vem som betalar. Det skriver Anna Törner i en krönika.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...
-
Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”
”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain mar...
-
Major investment in women’s health – for a more equal healthcare system
”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and D...